Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center



  • Subscribe to our e-Newsletter to receive email updates:

  • Related Articles

    Most Recent


    Join Us

    News: HRAS mutations

    Melanoma Drug Risks Studied

    Friday, March 23rd, 2012

    Melanoma patients who are treated with new oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. A new study co-authored by Vanderbilt-Ingram Cancer Center investigators and researchers from 12 other cancer centers discovered clues that may explain what is triggering these secondary cancers. VICC’s Igor Puzanov, M.D., assistant professor […]